Just saw DAWN stock absolutely popped off yesterday - jumped like 65% after Servier agreed to buy them out at $21.50 a share. Wild to see a biotech move like that, especially in the pediatric space where they were focused on low-grade glioma treatments. The deal's supposed to close sometime next quarter. Honestly, moves like this remind me that even in biotech there are those leg day quotes moments where you gotta push through the grind to see real gains. Anyway, pretty solid exit for the company if the deal actually closes as planned.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin